Gastroesophageal Cancer

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced gastroesophageal adenocarcinoma, according to the agents’ manufacturers.

Patients who underwent cancer surgery had an increased risk for venous thromboembolism for up to 1 year after the procedure, results from a retrospective study published in JAMA Network Open showed.

Results from the American Association for Cancer Research’s annual Cancer Progress Report revealed that the age-adjusted overall cancer death rate in the U.S. fell by 33% between 1991 and 2020.

The addition of pembrolizumab to chemotherapy significantly extended survival among patients with advanced HER2-negative gastric or gastroesophageal junction cancer, according to results of the phase 3 KEYNOTE-859 study.

Tislelizumab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in OS vs. chemotherapy alone among patients with PD-L1-positive, advanced gastric or gastroesophageal junction adenocarcinoma.

Adding regorafenib to best supportive care significantly increased survival rates compared with placebo among patients with refractory advanced gastroesophageal cancer, results of the randomized, phase 3 INTEGRATE IIa trial showed.

First-line pembrolizumab remained effective, safe and noninferior to chemotherapy among certain patients with PD-L1-positive advanced gastric, gastroesophageal junction cancer, according to follow-up results of the KEYNOTE-062 study.

The FDA approved pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with locally advanced or metastatic esophageal or gastroesophageal carcinoma.

First-line pembrolizumab appeared noninferior to chemotherapy and led to fewer adverse events among certain patients with advanced gastric or gastroesophageal junction cancer, according to results of the phase 3 KEYNOTE-062 study.

The American Cancer Society approved $36.1 million in funding for 79 research and training grants.